RCMNY
PCRX icon

Rubric Capital Management (New York)’s Pacira BioSciences PCRX Stock Holding History

Rubric Capital Management (New York)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-491,322
Closed -$16.6M – 69
2023
Q4 		$16.6M Buy
491,322
+31,685
+7% +$927K 0.34% 42
2023
Q3 		$14.1M Buy
+459,637
New +$16.6M 0.53% 44

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Rubric Capital Management (New York)'s PCRX Position: Q1 2024 in Review

Rubric Capital Management (New York) sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 491,322 shares — an estimated $16.6M sold.

Rubric Capital Management (New York) first reported a position in PCRX in Q3 2023 and held it in 2 quarters. The position peaked at $16.6M in Q4 2023. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

  • Rubric Capital Management (New York) reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 491,322 Pacira BioSciences shares in Q1 2024, an estimated $16.6M.
  • Rubric Capital Management (New York) first reported a position in Pacira BioSciences in Q3 2023 and held it in 2 quarters.
  • Rubric Capital Management (New York)'s Pacira BioSciences position peaked at $16.6M in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2024, filed 10 May 2024.